This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Exact Sciences

Ira P. emails, I follow you every day, both on RealMoney and Twitter. I think you are the most objective, bar none! Can you please write about Cadence Pharmaceuticals(CADX)?

Cadence is hoping that FDA approves Ofirmev, an intravenous formulation of acetaminophen, on Nov. 4. For that to happen, FDA inspectors need to give the all clear to a Baxter (BAX) manufacturing plant where Ofirmev is made. "Market chatter" says FDA completed its plant re-inspection but Cadence, to date, hasn't confirmed publicly.

My sense is that investors largely expect the FDA to be assuaged by Baxter's remediation efforts at the Ofirmev manufacturing plant and that the drug will be approved on the Nov. 4 approval decision date. After that, I think opinions on mixed on the drug's commercial success.

Fan mail from Bob M.: "Your job is to write biased articles. You comment on stocks because it's fun. You have zero background in biotechnology, you have no medical or scientific credentials. Talk about leading lemmings over the cliff. Why would anyone believe a word that you say? TheStreet is certainly getting what they payed [sic] for, if they hired a stooge."

More fan mail from Shantanu: "Aren't you a big fat lair [sic]? You lied before Vivus meeting and 85% of your lair [sic] hedge fund friends lied. How could you live with this type of unethical life?? Shame on you."

One more fan letter, for fun. Asif A. gets creative, although he's punctuationally challenged: "You [BLEEP] can't see anybody else make money. And you are pretty ugly too. How is the woman situation with you?, probably not good. thats why you are writing stupid articles. O, lets do this. if Silenor becomes very successful, can we all come [BLEEP] you [BLEEP BLEEP BLEEP.] put your money where your mouth is, or should I say [BLEEP]. LOL"

LOL, indeed.

Lastly, Adrian S. emails, "Really enjoy your articles. I sent you one email on this already and surprised you haven't jumped in on this yet. Labopharm(DDSS) looks to have a lot of promise at this juncture, having just launched Oleptro in the U.S. with their partner Angelini. With Canadian Oleptro approval and tramadol/acetaminophen combo approval in Europe by year's end I think it makes for an exciting near term story. What are your thoughts?"

Not so fast, Adrian. Oleptro's U.S. launch isn't going well, even slower than expectations, which weren't all that high to begin with. And while the positive opinion from European regulators for the tramadol/acetaminophen combo is encouraging, launch is probably a year away and may be met with the same indifference there as tramadol.

Labopharm is still a show-me stock.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CADX $0.00 0.00%
DCTH $0.49 2.20%
EXAS $9.09 -1.50%
TSPT $30.00 0.67%
SQNM $1.78 0.00%


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs